Several other equities research analysts have also recently issued reports on MDG1. Independent Research set a €12.50 ($15.43) target price on MediGene and gave the stock a neutral rating in a research note on Wednesday, December 6th. Baader Bank set a €19.00 ($23.46) target price on MediGene and gave the stock a buy rating in a research note on Monday, December 11th.
MDG1 stock traded up €1.75 ($2.16) during midday trading on Friday, hitting €15.50 ($19.14). 616,301 shares of the company’s stock were exchanged, compared to its average volume of 306,207. MediGene has a 1-year low of €8.53 ($10.53) and a 1-year high of €19.27 ($23.79).
ILLEGAL ACTIVITY WARNING: This story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://stocknewstimes.com/2018/04/17/oddo-bhf-analysts-give-medigene-mdg1-a-13-00-price-target.html.
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.